BidaskClub lowered shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

Several other brokerages have also issued reports on ADAP. Leerink Swann restated an outperform rating and set a $15.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, September 8th. Zacks Investment Research upgraded Adaptimmune Therapeutics from a hold rating to a buy rating and set a $9.75 target price for the company in a research report on Wednesday, October 4th. TheStreet upgraded Adaptimmune Therapeutics from a d rating to a c rating in a research report on Thursday, November 2nd. ValuEngine lowered Adaptimmune Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, SunTrust Banks restated a buy rating and set a $10.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $11.58.

Adaptimmune Therapeutics (NASDAQ:ADAP) opened at $7.00 on Wednesday. Adaptimmune Therapeutics has a 12-month low of $3.85 and a 12-month high of $9.29. The stock has a market capitalization of $650.23 and a P/E ratio of -9.33.

Several institutional investors have recently bought and sold shares of ADAP. Alps Advisors Inc. raised its stake in shares of Adaptimmune Therapeutics by 4.9% during the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock valued at $287,000 after acquiring an additional 2,996 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 43.7% during the second quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock valued at $5,941,000 after acquiring an additional 402,324 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics during the second quarter valued at approximately $242,000. Virtu KCG Holdings LLC raised its stake in shares of Adaptimmune Therapeutics by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 26,105 shares in the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in shares of Adaptimmune Therapeutics during the second quarter valued at approximately $156,000. 54.24% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://theolympiareport.com/2017/12/24/adaptimmune-therapeutics-adap-stock-rating-lowered-by-bidaskclub.html.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.